Credit Suisse’s BioMarin Pharmaceuticals BMRN Stock Holding History

Credit Suisse’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-108,300	Closed	-$9.57M	–	3673
2021 Q4	$9.57M	Sell	108,300 -8,500	-7%	-$701K	0.01%	1537
2021 Q3	$9.03M	Sell	116,800 -18,400	-14%	-$1.45M	0.01%	1596
2021 Q2	$11.3M	Sell	135,200 -83,100	-38%	-$6.59M	0.01%	1482
2021 Q1	$16.5M	Buy	218,300 +17,900	+9%	+$1.46M	0.01%	1272
2020 Q4	$17.6M	Buy	200,400 +125,700	+168%	+$9.97M	0.01%	1246
2020 Q3	$5.68M	Buy	+74,700	New	+$7.56M	﹤0.01%	1711
2015 Q1	–	Sell	-85,000	Closed	-$7.68M	–	4366
2014 Q4	$7.68M	Hold	85,000	–	–	0.01%	1450
2014 Q3	$6.13M	Sell	85,000 -85,300	-50%	-$5.61M	0.01%	1607
2014 Q2	$10.6M	Buy	170,300 +5,300	+3%	+$320K	0.01%	1349
2014 Q1	$11.3M	Buy	+165,000	New	+$12.2M	0.01%	1168

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Credit Suisse's BMRN Position: Q1 2024 in Review

Credit Suisse reduced its BioMarin Pharmaceuticals (BMRN) stake by 8.1% in Q1 2024, selling an estimated $2.27M and leaving 286,650 shares worth $25M. The position accounts for 0.02% of the portfolio, ranked #571.

Credit Suisse first reported a position in BMRN in Q2 2013 and has held it in 44 quarters since. The position peaked at $82.9M in Q3 2014. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2024.

Credit Suisse held 286,650 shares of BioMarin Pharmaceuticals worth $25M as of Q1 2024.
Credit Suisse sold 25,343 BioMarin Pharmaceuticals shares in Q1 2024, an estimated $2.27M.
BioMarin Pharmaceuticals made up 0.02% of Credit Suisse's portfolio in Q1 2024, its #571 holding.
Credit Suisse first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 44 quarters since.
Credit Suisse's BioMarin Pharmaceuticals position peaked at $82.9M in Q3 2014.
560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.